Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial

Michael Friedlander, Linda Mileshkin, Janine Lombard, Sophia Frentzas, Bo Gao, Michelle Wilson, Tarek Meniawy, Sally Baron-Hay, Karen Briscoe, Nicole McCarthy, Christos Fountzilas, Andres Cervantes, Ruimin Ge, John Wu, Alexander Spira

Research output: Contribution to journalArticlepeer-review


Background: The aim of this study was to investigate the antitumour activity, safety, and tolerability of pamiparib plus tislelizumab in patients with previously treated advanced solid tumours. Methods: In this study, patients were enrolled into eight arms by tumour type. All received pamiparib 40 mg orally twice daily plus tislelizumab 200 mg intravenously every 3 weeks. The primary endpoint was objective response rate (ORR), assessed by the investigator per Response Evaluation Criteria in Solid Tumours v1.1. Secondary endpoints included duration of response (DoR), safety, and tolerability. Results: Overall, 180 patients were enrolled. In the overall population, the ORR was 20.0% (range: 0–47.4 across study arms), with median DoR of 17.1 months (95% confidence interval [CI]: 6.2, not estimable [NE]). The highest ORR was observed in the triple-negative breast cancer (TNBC) arm (patients with BRCA1/2 mutations and/or homologous recombination deficiency) (ORR: 47.4%; median DoR: 17.1 months [95% CI: 3.0, NE]). Treatment-emergent adverse events (TEAEs) of ≥Grade 3 occurred in 61.7% of patients. Serious TEAEs occurred in 50.0% of patients. Conclusions: Pamiparib plus tislelizumab showed a variable level of antitumour activity in patients with advanced solid tumours, with the highest ORR in TNBC and was associated with a manageable safety profile. Clinical trial registration: NCT02660034.

Original languageEnglish
Pages (from-to)797-810
Number of pages14
JournalBritish Journal of Cancer
Issue number5
Publication statusPublished - 21 Sept 2023

Cite this